Predictive imaging marker of bevacizumab efficacy: Perfusion MRI

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1046-1047

  Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CEDIRANIB; ANGIOGENESIS INHIBITOR;

ACCURACY; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; SURVIVAL TIME; TREATMENT DURATION; BRAIN CORTEX; BRAIN NEOPLASMS; FEMALE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN NEOPLASMS; CEREBRAL CORTEX; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84943251951     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov067     Document Type: Editorial

References (12)

1. Chamberlain MC. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;67(11): 2089; author reply 2089.
2. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66(8):1258-1260.
3. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
4. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69(13): 5296-5300.
5. Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21(8):1723-1727.
6. Zhang WKT, Solomon J, Reynolds RC, et al. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. Paper presented at: The International Society for Magnetic Resonance in Medicine, Hawaii, USA. 2009.
7. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
8. Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(21):2049.
9. Schmainda KM, Prah M, Connelly J, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014;16(6):880-888.
10. Kickingereder P, Wiestler B, Burth S, et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 2015;17(8):1139-1147.
11. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
12. Ellingson BM, Sahebjam S, Kim HJ, et al. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol. 2014;35(4):673-679.